Biogen increases financial guidance despite 25% revenue drop

The Cambridge drug company reported in its quarterly earnings Thursday that its revenue has dropped 25% over the last year, but investors are still bullish. In fact, the Cambridge biotech has upped its financial guidance by a minimum of $2 million for the 2021 fiscal year, bolstered by its growing multiple sclerosis portfolio and an…

Read More

The Petri Dish: Former Genzyme CFO joins biologics startup

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here’s The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.…

Read More